Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:company
|
| gptkbp:acquiredBy |
gptkb:TypeZero_Technologies_(2018)
|
| gptkbp:category |
gptkb:biotechnology
gptkb:technology healthcare |
| gptkbp:CEO |
gptkb:Kevin_Sayer
|
| gptkbp:competitor |
gptkb:Medtronic
gptkb:Abbott_Laboratories gptkb:Senseonics |
| gptkbp:country |
gptkb:United_States
|
| gptkbp:focus |
diabetes management
|
| gptkbp:founded |
1999
|
| gptkbp:founder |
gptkb:Scott_Glenn
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
DexCom
|
| gptkbp:industry |
medical devices
|
| gptkbp:market |
global
|
| gptkbp:notableProduct |
gptkb:Dexcom_G6
gptkb:Dexcom_G7 |
| gptkbp:numberOfEmployees |
over 7,000
|
| gptkbp:product |
continuous glucose monitoring systems
|
| gptkbp:publiclyTraded |
gptkb:NASDAQ
|
| gptkbp:revenue |
$2.91 billion (2022)
|
| gptkbp:stockSymbol |
gptkb:NASDAQ
gptkb:DXCM |
| gptkbp:type |
gptkb:public_company
|
| gptkbp:website |
https://www.dexcom.com/
|
| gptkbp:bfsParent |
gptkb:NASDAQ-100
|
| gptkbp:bfsLayer |
5
|